Printer Friendly

LECTEC RESPONDS TO FDA ADVISORY PANEL INVESTIGATING REPORTS OF ADVERSE REACTIONS OF NICOTINE PATCHES

 LECTEC RESPONDS TO FDA ADVISORY PANEL INVESTIGATING REPORTS
 OF ADVERSE REACTIONS OF NICOTINE PATCHES
 MINNETONKA, Minn., July 14 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) today issued an announcement concerning an advisory panel reviewing reports of adverse reactions of nicotine patches. LecTec (NASDAQ: LECT) released information concerning its development of a nicotine-free smoking cessation patch, considered to be a safer and less toxic future alternative to the current nicotine patches.
 Based on concerns that a nicotine patch may not be the most effective or safe product for smoking cessation, LecTec researchers sought a safer medication. An agreement was jointly announced between the University of Minnesota and LecTec in January 1992, for a nicotine- free smoking cessation product. Under the terms of the agreement, a transdermal and an oral dosage form of a non-nicotine active ingredient for smoking cessation are being developed.
 Human and animal studies have demonstrated the non-addictive properties of the nicotine-free active. Studies also indicate that the future transdermal product will be less toxic and, thus, safer to use than existing nicotine-containing products. A patent has been filed and is pending.
 LecTec has been in contact with several prominent partners and expects soon to finalize an alliance to assure expeditious distribution of the future product. The company has two FDA registered pharmaceutical manufacturing facilities and is positioned to meet market volume projections.
 Nicotine is known to be toxic and can induce symptoms of nausea, vomiting, headache, dizziness and neurological stimulation which causes palpitation of the heart, increased blood pressure, accelerated breathing, perspiration and salivation. The dangers of smoking are well known.
 LecTec is one of the pioneers in the research of monolithic transdermal delivery systems for various drugs. Among the first projects pursued by the company was a transdermal dosage form for nicotine. The product was planned to be used as a smoking cessation treatment. Prototype products were submitted to an internationally recognized pharmaceutical company and a patent position established.
 The LecTec nicotine delivery system was promising and demonstrated unique advantages over other transdermal technologies. However, concern arose among the company's researchers in 1987 regarding potential shortcomings and dangers of a nicotine patch for smoking cessation.
 Research and results of smoking cessation therapies recently presented by the University of Minnesota Medical School highlighted limitations of current nicotine-containing smoking cessation products (Smoking Cessation Update and Intervention Strategies, May 29, 1992). Various medical clinics, such as Park Nicollet of Minneapolis and the world famous Mayo Clinic, have established programs using behavioral therapies to enhance current smoking cessation products ("Crushing Out Smoking Addiction," Robert D. Christensen, M.D., General Surgery, Park- Nicollet Clinic, Minnesota Medicine, Vol. 73, No. 4, March, 1990, p. 44). Noted Dr. Richard D. Hunt, director of the Nicotine Dependence Center at the Mayo Clinic, Rochester, Minn., "By itself, the patch isn't magic."
 In the United States alone, there are an estimated 50 million smokers. The potential market in the United States for smoking cessation products is projected to exceed $1 billion. The market is currently faced with demand far exceeding supply and little product differentiation among the transdermals, all of which contain nicotine as the active ingredient.
 LecTec Corporation is a medical company that develops, manufactures and markets a variety of skin-related products. In addition to transdermal drug delivery products, LecTec also produces cardiac diagnostic and monitoring electrodes, medical tapes and conductive- adhesive hydrogel polymers. LecTec is headquartered in Minnetonka, with an additional facility in Edina, Minn. The company is publicly traded on NASDAQ under the symbol LECT.
 -0- 7/14/92
 /CONTACT: Jan Jachimowicz of LecTec, 612-933-2291/
 (LECT) CO: LecTec ST: Minnesota IN: MTC SU:


KH -- MN014 -- 9278 07/14/92 16:59 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 14, 1992
Words:610
Previous Article:APPOINTMENT OF PUBLIC AFFAIRS DIRECTOR FOR GM'S NORTH AMERICAN OPERATIONS ANNOUNCED
Next Article:CHAPEL HILL SMOKED FISH COMPANY WITHDRAWS SMOKED FISH PRODUCT
Topics:


Related Articles
UNIVERSITY OF MINNESOTA, LECTEC AGREE TO DEVELOP NICOTINE-FREE SMOKING CESSATION TREATMENT
LECTEC SMOKING CESSATION PATCH DEVELOPMENT PROGRESSES; PATENT PENDING
LECTEC AND UNIVERSITY OF MINNESOTA PURSUE SAFER ALTERNATIVE TO NICOTINE FOR SMOKING CESSATION PATCHES
LEDERLE EXTENDS PROSTEP REBATE THROUGH END OF YEAR TO MAKE PRESCRIPTION NICOTINE PATCH MORE ACCESSIBLE IN LIGHT OF FDA BAN ON OVER-THE-COUNTER...
CNS AND LECTEC SIGN LETTER OF INTENT FOR MARKETING ALLIANCE; CNS WILL MARKET LECTEC'S ANALGESIC PAIN PATCH IN U.S. AND CANADA
CYGNUS' NICOTROL(R) RECEIVES FDA ADVISORY PANEL RECOMMENDATION FOR OVER-THE-COUNTER SALE
IN RESPONSE TO MEDIA INQUIRIES REGARDING THE MARKETING APPROVAL OF NICOTROL, SMITHKLINE BEECHAM ISSUED THE FOLLOWING STATEMENT:
THE FOOD AND DRUG ADMINISTRATION APPROVES SMITHKLINE BEECHAM'S NICODERM CQ FOR OVER-THE-COUNTER USE
Sano Corporation Reports Positive Results From Phase II Trial Of New Therapeutic For Smoking Cessation
A patch of all trades: transdermal systems use nonwovens to ease pain or offer relief.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters